IA
RETA

IFP Advisors’s Reata Pharmaceuticals, Inc. Class A Common Stock RETA Stock Holding History

IFP Advisors’s Portfolio RETA Stock Details RETA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-300
Closed -$51.7K – 3404
2023
Q3 		$51.7K Hold
300
– – ﹤0.01% 1537
2023
Q2 		$30.6K Hold
300
– – ﹤0.01% 1822
2023
Q1 		$10.7K Sell
300
-21
-7% -$1.23K ﹤0.01% 2255
2022
Q4 		$12K Sell
321
-102
-24% -$3.51K ﹤0.01% 3294
2022
Q3 		$19K Hold
423
– – ﹤0.01% 3152
2022
Q2 		$19K Hold
423
– – ﹤0.01% 2914
2022
Q1 		$19K Buy
423
+123
+41% +$3.65K ﹤0.01% 2914
2021
Q4 		$8K Buy
300
+250
+500% +$19.3K ﹤0.01% 2325
2021
Q3 		$5K Hold
50
– – ﹤0.01% 2589
2021
Q2 		$7K Hold
50
– – ﹤0.01% 2370
2021
Q1 		$5K Hold
50
– – ﹤0.01% 2444
2020
Q4 		$6K Hold
50
– – ﹤0.01% 2278
2020
Q3 		$5K Buy
+50
New +$6.25K ﹤0.01% 2208

IFP Advisors's RETA Position: Q4 2023 in Review

IFP Advisors sold out of Reata Pharmaceuticals, Inc. Class A Common Stock (RETA) in Q4 2023, closing a stake of 300 shares — an estimated $51.7K sold.

IFP Advisors first reported a position in RETA in Q3 2020 and held it in 13 quarters. The position peaked at $51.7K in Q3 2023. 0 funds tracked by Wall St. Rank hold RETA as of Q4 2023.

  • IFP Advisors reported no remaining Reata Pharmaceuticals, Inc. Class A Common Stock position as of Q4 2023 after selling out during the quarter.
  • IFP Advisors sold 300 Reata Pharmaceuticals, Inc. Class A Common Stock shares in Q4 2023, an estimated $51.7K.
  • IFP Advisors first reported a position in Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2020 and held it in 13 quarters.
  • IFP Advisors's Reata Pharmaceuticals, Inc. Class A Common Stock position peaked at $51.7K in Q3 2023.
  • 0 funds tracked by Wall St. Rank held Reata Pharmaceuticals, Inc. Class A Common Stock as of Q4 2023.

Based on IFP Advisors's 13F filing for Q4 2023, filed 9 Jan 2024.